| Name: | 3-Deoxy 3-Chloro Abiraterone |
| Catalogue No. | VL830022 |
| CAS No. | N/A |
| Molecular Formula | C24H30ClN |
| Molecular Weight | 367.96 |
| Status | Under Development |
| IUPAC Name | 1-((8R,9S,10R,13S,14S)-10,13-Dimethyl-17-(pyridin-3-yl)-2,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl)ethan-1-one |
| Description | 3-Deoxy 3-Chloro Abiraterone(CAS No: N/A) or 1-((8R,9S,10R,13S,14S)-10,13-Dimethyl-17-(pyridin-3-yl)-2,7,8,9,10,11,12,13,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl)ethan-1-one, it is poorly absorbed and is susceptible to hydrolysis by esterases and is an orally active inhibitor of the steroidal enzyme CYP17A1 that is used in the treatment of prostate cancer. |
| References | Goldberg, Tamara, and Evangelina Berrios-Colon. “Abiraterone (Zytiga), a Novel Agent for the Management of Castration-Resistant Prostate Cancer.” Pharmacy and Therapeutics, vol. 38, no. 1, 1 Jan. 2013, pp. 23–26, www.ncbi.nlm.nih.gov/pmc/articles/PMC3628169/. |
